logo
Amazon Web Services profits squeezed as AI arms race drives spending surge

Amazon Web Services profits squeezed as AI arms race drives spending surge

Geek Wire31-07-2025
Amazon Web Services is aiming to leverage its clout in the cloud for an AI advantage. (GeekWire File Photo)
An increase in Amazon Web Services spending cut into the cloud giant's profits in the second quarter as AWS raced to meet demand for AI against Microsoft, Google, and others.
While Amazon beat Wall Street's overall expectations, its shares fell in after-hours trading as investors focused on rising costs within the cloud unit, the company's biggest profit engine.
AWS revenue grew 17.5% year-over-year to $30.9 billion, in line with estimates. But the costs of competing in the AI arms race were evident in the cloud division's profits. AWS operating income grew less than 9% to $10.2 billion as its operating expenses surged to $20.7 billion, up from $16.9 billion a year earlier.
This resulted in an operating margin of 32.9% — the cloud giant's lowest profit-to-revenue ratio since late 2023, and well below the operating margin of nearly 40% in the first quarter.
On the company's earnings call with analysts, Amazon CFO Brian Olsavsky attributed the pressure on AWS's profit margin to a seasonal increase in stock-based compensation, unfavorable foreign exchange rates, and higher depreciation costs from ongoing investments in AI infrastructure.
Later on the call, analysts pressed Amazon CEO Andy Jassy to respond to a 'Wall Street narrative' that the company is falling behind rivals Microsoft and Google in pursuing the AI opportunity.
Amazon's results came a day after Microsoft disclosed annual revenue of more than $75 billion for its Azure cloud platform, with quarterly growth of 39%, far exceeding expectations.
Google Cloud's annual revenue run rate is more than $50 billion, with quarterly growth of 32% year-over-year, according to numbers disclosed by Google parent Alphabet last week.
AWS is a significantly larger business, with an annual revenue run rate of more than $123 billion, making it much more difficult to generate eye-popping growth rates.
But even at that size, Morgan Stanley analyst Brian Nowak asked Jassy if it would be possible for AWS growth to accelerate for the remainder of 2025, 'given the size of the opportunity' and the volume of the generative AI workloads expected to come online in the next 12 months.
While Jassy declined to give specific guidance for the AWS segment, he said he is 'optimistic about the AWS business' and its potential to accelerate.
He cited a combination of factors, including more enterprises resuming their migrations from on-premises data centers to the cloud, the expected increase in companies deploying AI applications into production, and more AWS capacity coming online in the coming months.
Jassy described long-term strategic advantages for AWS, including the fact that AI inference will eventually be treated as 'another building block' like compute, storage and database.
Because of this, he said, many customers will want to run their AI applications close to where their other applications and data already reside — creating a powerful advantage for Amazon, because 'there's just so many more applications and data running in AWS than anywhere else.'
Jassy said AWS has a key advantage with its custom-built chips, which he said offer 30% to 40% better price-performance for inference than other GPU providers.
He also pointed to what he called a 'very big difference' in security — alluding to problems that have plagued Microsoft without naming the company directly — and noted that AWS has a more significant, end-to-end set of AI services 'from the bottom of stack all the way to top.'
AI milestones for the company in the recent quarter included the launch of Kiro, a new agentic integrated development environment (IDE) that lets developers code in natural language, while the system automatically creates documentation and specs, and scans for security issues.
The company reported $31.4 billion in capital expenditures for the second quarter, up from nearly $25 billion in the first quarter, most of it related to technology infrastructure. Amazon's capex number is not directly comparable to Microsoft and Google due to its additional investments in fulfillment centers and its Project Kuiper satellite network.
Olsavsky said AWS will continue to invest more capital in data centers and other resources 'to pursue this unusually large opportunity that we have in generative AI.' Operating margins, he said, will 'fluctuate over time, driven in part by the level of investments we are making.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ...
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ...

Yahoo

time16 minutes ago

  • Yahoo

Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ...

Revenue: $11.5 million, attributed to the Sanofi collaboration. R&D Expenses: $78.4 million, with $8.0 million in non-cash stock-based compensation. Adjusted Cash R&D Spend: $70.4 million, a 3% decrease from the previous quarter. G&A Expenses: $17.6 million, with $7.4 million in non-cash stock-based compensation. Adjusted Cash G&A Spend: $10.2 million, a 6% increase from the previous quarter. Cash Balance (End of June): $963 million. Cash Balance (End of July): Approximately $1 billion, including proceeds from a follow-on offering and Gilead payment. Cash Runway: Extended into the second half of 2028. Gilead Collaboration Potential Payments: Up to $750 million, plus tiered royalties. Sanofi Collaboration Potential Milestones: Up to $975 million, with options for profit sharing or royalties. Warning! GuruFocus has detected 5 Warning Signs with KYMR. Release Date: August 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kymera Therapeutics Inc (NASDAQ:KYMR) reported positive results from the first KT-621 trial in healthy volunteers, exceeding expectations and surpassing the target product profile. The company has extended its cash runway into the second half of 2028, with a cash position of approximately $1 billion as of the end of July. Kymera Therapeutics Inc (NASDAQ:KYMR) announced two significant partnerships: one with Gilead for the development of an oral molecular glue degrader targeting CDK2, and another with Sanofi for the IRAK4 program. The company has completed long-term toxicity studies and selected doses for upcoming Phase 2b studies, indicating strong progress in its pipeline development. Kymera Therapeutics Inc (NASDAQ:KYMR) is building a robust oral immunology pipeline, with plans to unveil one new program per year to expand access to oral systemic advanced therapies. Negative Points Revenue for the second quarter of 2025 was $11.5 million, which may be considered low compared to the company's cash burn and R&D expenses. R&D expenses for the quarter were $78.4 million, indicating high operational costs that could impact profitability. The company is still in early stages of clinical trials for many of its programs, which means potential delays or failures could impact future growth. There is uncertainty regarding the translation of preclinical success to clinical efficacy, particularly for new targets like IRF5. The competitive landscape in the immunology space is evolving, and Kymera Therapeutics Inc (NASDAQ:KYMR) faces challenges in differentiating its products from existing therapies. Q & A Highlights Q: Could you provide some color on the decision to add a second dose in the Phase Ib study for KT-621? A: Nello Mainolfi, CEO, explained that both doses are within the range explored in the Phase I healthy volunteer study. Initially, they planned to explore one dose, but due to rapid enrollment and the ability to assess performance, they decided to explore an additional dose to ensure robust translation from healthy volunteers to patients. This decision helps refine the Phase IIb dose selection. Q: What factors influenced the dose selection for the Phase II studies? A: Nello Mainolfi stated that the dose selection was primarily based on healthy volunteer data. Other studies, including the Japanese study and GLP tox studies, confirmed their initial instincts. The data from these studies supported the dose selection without necessitating changes. Q: What are your expectations for the clinical efficacy measures in the Phase Ib study, particularly EASI-75 and NRS? A: Jared Gollob, CMO, emphasized that the primary objective is to show robust STAT6 degradation and a dupilumab-like biomarker effect. While clinical endpoints like EASI and pruritus NRS are exploratory, they expect to see impact similar to published dupilumab data at 28 days. Q: Can you confirm if the dose added to the Phase Ib is higher or lower than the original dose? A: Nello Mainolfi declined to specify whether the added dose is higher or lower, stating that both doses were tested in healthy volunteers. The main goal is to ensure the doses perform well in patients to inform Phase IIb dose selection. Q: What are your expectations for safety risks associated with complete STAT6 degradation? A: Jared Gollob noted that they have seen no safety signals in GLP tox studies or healthy volunteers. The safety profile was undifferentiated from placebo, and they expect similar results in the Phase Ib study. STAT6 is highly selective for IL-4/IL-13 pathways, and preclinical studies support its safety. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Telos Corp (TLSRP.PFD) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Telos Corp (TLSRP.PFD) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Yahoo

time16 minutes ago

  • Yahoo

Telos Corp (TLSRP.PFD) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Revenue: $36 million, a 26% increase, exceeding guidance range of $32.5 million to $34.5 million. Security Solutions Revenue: Approximately 90% of total company revenue. GAAP Gross Margin: 33.2%. Cash Gross Margin: 38.4%. Adjusted Operating Expenses: Approximately $900,000, better than guidance. Adjusted EBITDA: $400,000 profit, exceeding guidance range of a $2.1 million loss to a $600,000 loss. Operating Cash Flow: $7 million. Free Cash Flow: $4.6 million, or a 12.9% margin. Share Repurchases: $4 million deployed to repurchase approximately 1.5 million shares at $2.69 per share. Enrollment Centers: Expanded to 415 locations, a 43% increase since last earnings call. Warning! GuruFocus has detected 4 Warning Signs with Release Date: August 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue grew 26% in the second quarter to $36 million, exceeding guidance. Security solutions delivered approximately 90% of total company revenue, driving outperformance. Adjusted EBITDA improved significantly, returning to a profit with a $400,000 gain. Free cash flow was robust, improving by $16 million year over year to $4.6 million. The company resumed share repurchases, deploying $4 million to buy back shares. Negative Points Gross margins were lower year over year due to revenue mix changes. Secure networks segment experienced contraction, partially offsetting growth in security solutions. The company faces variability in gross margins due to fluctuating revenue streams. The TSA PreCheck program's renewals are down due to the five-year anniversary of COVID. Confidential IT security work details are limited, providing less transparency on growth drivers. Q & A Highlights Q: Can you discuss the progress of TSA PreCheck enrollments and the target for market share? A: Mark Bendza, CFO, stated that they are on track to reach 500 locations by the end of the year, with enrollments increasing alongside the number of locations. Despite a decline in renewals due to the five-year anniversary of COVID, new enrollments are driving year-over-year performance. Q: What is driving the sequential increase in gross margin? A: Mark Bendza explained that the increase is due to the mix of revenue streams, each with different margin profiles. The third quarter is expected to see higher margins due to growth drivers in Telos ID and the mix within those programs. Q: Can you provide more details on the confidential IT security work for the federal government? A: Mark Bendza mentioned that while they cannot disclose specifics, the work is a meaningful addition to their revenue stream. Mark Griffin added that Telos has a strong pipeline with over 200 opportunities, valued at over $4 billion, with significant awards expected in Q4 and Q1 next year. Q: How will the changes in DHS security lines affect TSA PreCheck enrollments? A: Mark Griffin stated that the changes are not expected to negatively impact enrollments. In fact, they may increase program visibility, with speed through the line remaining a critical component of TSA PreCheck. Q: What is the capital allocation strategy given the strong free cash flow? A: Mark Bendza indicated that the priority is to use free cash flow for share buybacks. They will consider opportunistic tuck-in acquisitions and transformational M&A opportunities if they provide clear value for shareholders. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

Repay Holdings Corp (RPAY) Q2 2025 Earnings Call Highlights: Navigating Growth and Challenges
Repay Holdings Corp (RPAY) Q2 2025 Earnings Call Highlights: Navigating Growth and Challenges

Yahoo

time16 minutes ago

  • Yahoo

Repay Holdings Corp (RPAY) Q2 2025 Earnings Call Highlights: Navigating Growth and Challenges

Revenue: $75.6 million, an increase of 1% year-over-year. Gross Profit: Declined by 2% year-over-year; impacted by client losses and political media contributions. Adjusted EBITDA: $31.8 million, with a margin of 42%. Adjusted Net Income: $19.1 million or $0.20 per share. Free Cash Flow: $22.6 million, with a 71% cash flow conversion rate. Cash and Liquidity: $163 million in cash and $413 million total liquidity. Net Leverage: Approximately 2.5 times. Share Repurchase: 7.9 million shares repurchased year-to-date for $38 million. Credit Union Clients: Increased to 353 clients. Supplier Network Growth: Grew 47% year-over-year to over 440,000 suppliers. Warning! GuruFocus has detected 1 Warning Sign with RPAY. Release Date: August 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Repay Holdings Corp (NASDAQ:RPAY) reported a sequential improvement in year-over-year growth with a 1% increase in revenue for Q2 2025. The company maintained strong adjusted EBITDA margins of 42% during the quarter. Repay Holdings Corp (NASDAQ:RPAY) achieved a 71% free cash flow conversion, demonstrating solid cash generation. The company onboarded several new clients in its financial solution vertical, including 10 new credit union wins. Repay Holdings Corp (NASDAQ:RPAY) repurchased approximately 5% of its outstanding shares, using $38 million to buy back 7.9 million shares. Negative Points Reported gross profit declined by 2% year-over-year, impacted by client losses and political media contributions. The business payment segment experienced a 5% year-over-year decline in reported gross profit. There was softness in the accounts receivable client base within the business payment segment. The company faced a 10-point headwind in business payments growth due to a client loss in 2024. Repay Holdings Corp (NASDAQ:RPAY) needs to address $220 million of convertible notes due in February 2026, which may require tapping into its revolver. Q & A Highlights Q: Can you explain the confidence behind the guidance for high single-digit growth in the second half of 2025, given the low single-digit growth in the first half? A: Thomas Sullivan, Interim CFO, explained that the normalized growth was negative 1% in Q2, excluding political media impacts. They expect sequential improvement in Q3 and further acceleration in Q4 as they lap previous client losses. The guidance for Q4 is high single-digit to low double-digit normalized growth. Q: How does Repay plan to manage the $220 million convertible notes due in February 2026? A: John Morris, CEO, stated that the company plans to prioritize using cash on hand to pay down the debt, but they will need to use their revolver to cover the remaining amount. The focus remains on organic growth investments and managing CapEx. Q: Are there any specific verticals or strategic areas for potential tuck-in M&A? A: John Morris mentioned that any M&A would need to be strategic, aligning with their current operations in consumer and business payments. They are looking for opportunities that could accelerate growth or provide a strategic advantage. Q: Is there potential to move upmarket into larger customers with the current platform? A: John Morris confirmed that they are investing in enterprise sales and enhancing their direct sales model. They are capitalizing on monetization opportunities and indirect partnerships, which should help them target larger enterprise opportunities within their existing verticals. Q: What is the current status of the mortgage payments market for card payments? A: John Morris noted that while there is a healthy pipeline and positive traction, it is not expected to be a significant contributor in 2025. The focus remains on building opportunities for future growth. Q: Can you provide an update on the recent RCS partnership with the POS provider? A: John Morris stated that they are in the process of implementations and are optimistic about the future of the relationship, though no significant updates are available at this time. Q: What is the mix between AR and AP in the B2B segment, given the softness in AR? A: John Morris indicated that the mix is approximately 60% AR and 40% AP. Q: Are there any specific areas of consumer softness, and are these trends temporary or cyclical? A: John Morris mentioned that they see resilient trends in auto, personal loans, and mortgage, but the auto sector remains challenged. They have not seen significant changes in consumer behavior, and trends remain consistent through July and early August. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store